| Name | DB2313 |
| Description | DB2313 (Carboximidamide) is a potent transcription factor PU.1 inhibitor, IC50=14 nM. DB2313 disrupts the interaction of PU.1 with target gene promoters. DB2313 induces apoptosis of acute myeloid leukemia (AML) cells, and has anticancer effects |
| In vitro | DB2313 reduces PU.1 binding to the promoters of E2f1, Junb, and Csf1r in acute myeloid leukemia (AML) cells, significantly impairing their proliferation, particularly in PU.1 URE–/– AML cells where it shows an IC50 of 7.1 μM with minimal impact on normal hematopoietic cells at comparable doses. This treatment also increases apoptosis by 3.5 times in PU.1 URE–/– AML murine cells and notably diminishes their clonogenic survival across successive replatings, culminating in a total loss of clonogenic capacity from the fourth replating onwards[1]. |
| In vivo | DB2313 (17 mg/kg; i.p.; three times per week for 3 weeks) treatment reduces leukemia progression and enhances survival in mice. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 3.53 mg/mL (4.98 mM), Sonication and heating to 70℃ are recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (1.41 mM), Sonication is recommended.
|
| Keywords | DB-2313 | DB2313 | DB 2313 | Apoptosis |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
| Related Compound Libraries | Apoptosis Compound Library | Bioactive Compound Library | Hematonosis Compound Library | Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library | Anti-Cancer Active Compound Library | Transcription Factor-Targeted Compound Library |
United States
